Versatope wins big at Massachusetts Life Science Innovators Day
First prize out of 32 competing biotech start-ups
LOWELL, Mass., June 19, 2018 – Versatope Therapeutics, Inc., received the first prize at the 11th Massachusetts Life Science Innovators (MALSI) conference that took place at the Harvard Club in Boston on May 31, 2018.
Versatope Therapeutics is a start-up biotechnology company developing a new class of potent immunotherapeutics using recombinant outer membrane vesicles (rOMVs) derived from probiotic bacteria. They deliver immunity with nano-size vesicles made by nature and optimized with a cutting edge technology platform.
The Massachusetts Life Sciences Innovation (MALSI) Day is the biggest day for life sciences startups and innovation in Massachusetts, bringing together scientific leaders and business experts with other scientists, post-docs, professors, entrepreneurs, innovators, and venture capitalists.
“Many innovations showcased at the Massachusetts Life Sciences Innovation Day will have a dramatic impact across the global life sciences sector,” said Abigail Barrow. “Versatope is a testament to the potential of start-up biotechnology companies and the promise their transformative technology platform represents to patients and their families living with severe and life-threatening diseases. We look forward to Versatope Therapeutics’ continued growth and contributions to this field.”
Lucie Rochard, PhD, Liaison for Scientific & Entrepreneurial Innovation Services, Massachusetts Biotechnology Council expressed similar enthusiasm in awarding the first prize to Versatope Therapeutics: “MassConnect has been an unparalleled portal to early stage innovation and talented and exceptional entrepreneurs, Christopher and the Versatope technology reinforce that, and we are really pleased and proud to present this award.”
“Our technology platform was well received by the judges and the attendees of the MALSI event,” said Christopher Locher, Ph.D., Chief Executive Officer and Founder, Versatope Therapeutics. “It is an honor to receive the first prize out of 32 biotech start-up companies.”
About Versatope Therapeutics
Versatope Therapeutics is a company focused on the development of proprietary immunotherapeutics using rOMVs as an expression and delivery technology. Versatope’s rOMV technology has the potential to transform medicine by providing durable immunity to infectious diseases and other indications with a single treatment. The combination of semi-synthetic biology and chemistry, R&D experience, along with leading intellectual property portfolio, empowers the therapeutic applications of the rOMV technology and the creation of a new class of potent immunotherapeutics.
Learn more about Versatope Therapeutics at Versatope.com; Follow us on Twitter: @VersatopeRx.
Christopher Locher, Ph.D.,
Chief Executive Officer and Founder